Voclosporin in Adolescents With Lupus Nephritis

Description

The purpose of this study is to assess the efficacy and safety of voclosporin compared to placebo in achieving renal response following 24 weeks of therapy in adolescents with active lupus nephritis (LN).

Conditions

Adolescent Lupus Nephritis

Study Overview

Study Details

Study overview

The purpose of this study is to assess the efficacy and safety of voclosporin compared to placebo in achieving renal response following 24 weeks of therapy in adolescents with active lupus nephritis (LN).

A Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Efficacy, Safety and Pharmacokinetics of Voclosporin in Adolescents With Lupus Nephritis

Voclosporin in Adolescents With Lupus Nephritis

Condition
Adolescent Lupus Nephritis
Intervention / Treatment

-

Contacts and Locations

Chapel Hill

UNC-Chapel Hill, Chapel Hill, North Carolina, United States, 27514

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Previous diagnosis of systemic lupus erythematosus (SLE) as per the 2019 EULAR/ ACR classification criteria.
  • * Subjects with kidney biopsy confirmed active lupus nephritis.
  • * Estimated glomerular filtration rate (eGFR) \<60 mL/minute/1.73 m2 at screening.
  • * Current or medical history of:
  • * Congenital or acquired immunodeficiency.
  • * Clinically significant drug or alcohol abuse prior to screening.
  • * Malignant neoplasm.
  • * Lymphoproliferative disease or previous total lymphoid irradiation.
  • * Known severe viral infections within 3 months of screening; or known human immunodeficiency virus infection, or hepatitis B or C virus infection at any time prior to screening.
  • * Active tuberculosis (TB) or known history of TB/evidence of old TB if not taking prophylaxis with isoniazid.
  • * Currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected to require dialysis during the study period.
  • * Other known clinically significant active medical conditions, for which the condition or the treatment of the condition may affect the study assessments or outcomes.
  • * Currently taking or known need for any of the following medications:
  • * Immunosuppression biologic agents within 12 weeks prior to randomization, cyclophosphamide, calcineurin inhibitors (CNIs) and live attenuated vaccines, initiation or dose change of ACE inhibitors/ARBs within 4 weeks prior to randomization, IV corticosteroids and IV immunoglobulin within 2 weeks prior to screening, strong CYP3A4/5 inhibitors and inducers within 2 weeks prior to randomization.

Ages Eligible for Study

12 Years to 17 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Aurinia Pharmaceuticals Inc.,

Study Record Dates

2025-01